Jonathan Corren

Jonathan Corren

Auto-generated profile, based on publicly available information

Jonathan Corren

David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JCJonathan Corren
Jonathan Corren
JPJane R. Parnes
Jane R. Parnes
LWLiangwei Wang
Liangwei Wang
MMMay Mo
May Mo
SRStephanie L. Roseti
Stephanie L. Roseti
RMRené van der Merwe
René van der Merwe
In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell–derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids.

1 October 2016 in Chest
Verified
Journal Article
Open access
JCJonathan Corren
Jonathan Corren
SWSteven Weinstein
Steven Weinstein
LJLindsay Janka
Lindsay Janka
JZJames Zangrilli
James Zangrilli
MGMargaret Garin
Margaret Garin
IL-5, a mediator of eosinophil activity, is an important potential treatment target in patients with uncontrolled asthma. The efficacy of reslizumab, a humanized anti-human IL-5 monoclonal antibody, has been characterized in patients with blood eosinophils ≥ 400 cells/μL. This study further characterizes the efficacy and safety of reslizumab in patients with poorly-controlled asthma, particularly those with eosinophils < 400 cells/μL. Patients were randomly assigned to intravenous reslizumab 3.0 mg/kg or placebo once every 4 weeks for 16 weeks. The primary end point was the change in FEV1 from baseline to week 16. Secondary measures included Asthma Control Questionnaire-7 (ACQ-7) scores, use of short-acting β-agonists (SABAs), and FVC. Four hundred ninety-two patients received ≥ 1 dose of placebo (n = 97) or reslizumab (n = 395). In the overall population, mean FEV1 change from baseline to week 16 was not significantly different between reslizumab and placebo, and no significant relationship was detected between treatment, baseline blood eosinophils and change in FEV1. In the subgroup of patients with baseline eosinophils < 400 cells/μL, patients treated with reslizumab showed no significant improvement in FEV1 compared with those receiving placebo. In the subgroup with eosinophils ≥ 400 cells/μL, however, treatment with reslizumab was associated with much larger improvements in FEV1, ACQ-7, rescue SABA use, and FVC compared with the placebo group. Reslizumab was well tolerated, with fewer overall adverse events compared with placebo (55% vs 73%). Reslizumab was well tolerated in patients with inadequately controlled asthma. Clinically meaningful effects on lung function and symptom control were not seen in patients unselected for baseline eosinophils. ClinicalTrials.gov; No.: NCT01508936; URL: www.clinicaltrials.gov.

15 April 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JCJonathan Corren
Jonathan Corren
WBWilliam Busse
William Busse
EMEli O. Meltzer
Eli O. Meltzer
LMLyndon Mansfield
Lyndon Mansfield
GBGeorge Bensch
George Bensch
SLShao-Lee Lin
Shao-Lee Lin
Rationale: IL-4 and IL-13 share many biological functions important in the development of allergic airway inflammation and are implicated in the pathogenesis of asthma. AMG 317 is a fully human monoclonal antibody to IL-4Rα that blocks both IL-4 and IL-13 pathways. Objectives: To evaluate efficacy and safety of AMG 317 in patients with moderate to severe asthma. Methods: In this phase 2, randomized, double-blind, placebo-controlled study, patients received weekly subcutaneous injections of placebo or AMG 317 (75–300 mg) for 12 weeks, followed by a 4-week follow-up period. The primary endpoint was change from baseline at Week 12 in Asthma Control Questionnaire (ACQ) symptom score. Measurements and Main Results: Mean ACQ change (SE) was −0.49 (0.09) in placebo (n = 74), and −0.43 (0.11), −0.58 (0.12), and −0.70 (0.09) in the AMG 317 75 mg (n = 73), 150 mg (n = 73), and 300 mg (n = 74) groups, respectively (treatment effect P = 0.25). No statistically significant differences were observed in the secondary endpoints. Numerical decreases in number of and time to exacerbations were noted in patients receiving AMG 317 150 mg and 300 mg. Preplanned analyses by tertile of baseline ACQ revealed that patients with higher baseline ACQ scores (≥2.86) were more likely to respond to AMG 317. Serious adverse events were reported in three patients, each noted as not related to study drug. Conclusions: AMG 317 did not demonstrate clinical efficacy across the overall group of patients. Clinically significant improvements were observed in several outcome measures in patients with higher baseline ACQ scores. AMG 317 was safe and well tolerated in this study population. Clinical trial registered with www.clinicaltrials.gov (NCT 00436670).

11 May 2009 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
JCJ. Corren
J. Corren
TCT. B. Casale
T. B. Casale
BLB. Lanier
B. Lanier
RBR. Buhl
R. Buhl
SHS. Holgate
S. Holgate
PJP. Jimenez
P. Jimenez

1 July 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
JCJonathan Corren
Jonathan Corren
AMAndrew Menzies-Gow
Andrew Menzies-Gow
GCGeoffrey Chupp
Geoffrey Chupp
EIElliot Israel
Elliot Israel
SKStephanie Korn
Stephanie Korn
GCGene Colice
Gene Colice
Rationale: Tezepelumab reduced exacerbations in patients with severe, uncontrolled asthma across a range of baseline blood eosinophil counts and fractional exhaled nitric oxide levels, and irrespective of allergy status, in the phase 2b PATHWAY (Study to Evaluate the Efficacy and Safety of MEDI9929 [AMG 157] in Adult Subjects With Inadequately Controlled, Severe Asthma; NCT 02054130) and phase 3 NAVIGATOR (Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma; NCT 03347279) trials. Objectives: To examine the efficacy and safety of tezepelumab in additional clinically relevant subgroups using pooled data from PATHWAY and NAVIGATOR. Methods: PATHWAY and NAVIGATOR were randomized, double-blind, placebo-controlled trials with similar designs. This pooled analysis included patients with severe, uncontrolled asthma (PATHWAY, 18–75 years old; NAVIGATOR, 12–80 years old) who received tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. The annualized asthma exacerbation rate over 52 weeks and secondary outcomes were calculated in the overall population and in subgroups defined by inflammatory biomarker levels or clinical characteristics. Measurements and Main Results: Overall, 1,334 patients were included (tezepelumab, n = 665; placebo, n = 669). Tezepelumab reduced the annualized asthma exacerbation rate versus placebo by 60% (rate ratio, 0.40 [95% confidence interval, 0.34–0.48]) in the overall population, and clinically meaningful reductions in exacerbations were observed in tezepelumab-treated patients with type 2–high and type 2–low disease by multiple definitions. Tezepelumab reduced exacerbation-related hospitalization or emergency department visits and improved secondary outcomes compared with placebo overall and across subgroups. The incidence of adverse events was similar between treatment groups. Conclusions: Tezepelumab resulted in clinically meaningful reductions in exacerbations and improvements in other outcomes in patients with severe, uncontrolled asthma, across clinically relevant subgroups. Clinical trials registered with www.clinicaltrials.gov (NCT 02054130 [PATHWAY], NCT 03347279 [NAVIGATOR]).

12 September 2013 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
JCJonathan Corren
Jonathan Corren